![]() |
市场调查报告书
商品编码
1497676
癌症生物标记市场:按生物标记类型、癌症类型、技术、应用、最终用户 - 2024-2030 年全球预测Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
癌症生物标记市场规模预计2023年为283.1亿美元,2024年达到312.3亿美元,预计2030年将达到577.5亿美元,复合年增长率为10.71%。
癌症生物标记是可以在身体部位(例如血液或组织)中测量的物质或过程,可以帮助检测体内是否有癌症。蛋白质、基因突变或其他分子显示身体可能正在对抗癌症。癌症生物标记的使用不断扩大,主要是由于技术进步提高了这些测试的准确性和速度。此外,人们对个人化医疗的认识不断提高,透过为每位患者提供量身定制的治疗来改善治疗结果,从而扩大了癌症生物标记的应用。然而,测试中的假阳性或假阴性可能导致错误的治疗决策,并可能对市场成长构成挑战。然而,目前难以早期检测的癌症类型(例如胰腺癌和卵巢癌)的生物标记的开拓有可能扩大市场扩张的范围。此外,将生物标记与数位健康资讯系统结合有可能增强患者监测和持续治疗协调。
主要市场统计 | |
---|---|
基准年[2023] | 283.1亿美元 |
预测年份 [2024] | 312.3亿美元 |
预测年份 [2030] | 577.5亿美元 |
复合年增长率(%) | 10.71% |
区域洞察
在美洲,强大的医疗基础设施以及对癌症筛检和早期检测的高度认识正在推动对癌症生物标记的需求。该地区,尤其是美国,是许多致力于开发新生物标记并将其商业化的大型生物技术和医疗保健公司的所在地。该市场从政府的支持措施和研发方面的大量投资中受益匪浅。由于西欧完善的医疗保健系统以及中东和非洲国家政府对癌症研究的支持不断增加,EMEA(欧洲、中东和非洲)地区也是癌症生物标记的重要市场。由于医疗成本上升和癌症盛行率增加,亚太地区癌症生物标记领域呈现快速成长。中国、日本和印度等国家正大力投资医疗基础设施和研究,推动成长。此外,这些经济体的中产阶级人口不断增长,为实施先进的医疗保健解决方案(包括癌症生物标记)创造了巨大的机会。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在癌症生物标记市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对癌症生物标记市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在癌症生物标记市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[197 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.
Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 28.31 billion |
Estimated Year [2024] | USD 31.23 billion |
Forecast Year [2030] | USD 57.75 billion |
CAGR (%) | 10.71% |
Regional Insights
In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.
Market Insights
The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]
Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]
Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage